(Q47878296)

6 February 2018

title

Endostatin gene transfection using a cationic lipid: advantages of transfection before tumor cell inoculation and repeated transfection (English)

1 reference

6 February 2018

author

Akimitsu Konishi

5

1 reference

6 February 2018

author name string

Motoki Yano

1

1 reference

6 February 2018

Yoshiaki Nakashima

2

1 reference

6 February 2018

Yoshihiro Kobayashi

3

1 reference

6 February 2018

Kotaro Mizuno

4

1 reference

6 February 2018

Hidefumi Sasaki

6

1 reference

6 February 2018

Ichiro Fukai

7

1 reference

6 February 2018

Ronald K Scheule

8

1 reference

6 February 2018

Yoshitaka Fujii

9

1 reference

6 February 2018

publication date

1 May 2004

1 reference

6 February 2018

published in

Cancer Gene Therapy

1 reference

6 February 2018

volume

11

1 reference

6 February 2018

issue

5

1 reference

6 February 2018

page(s)

354-362

1 reference

6 February 2018

Angiogenesis in cancer, vascular, rheumatoid and other disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Improving protein therapeutics with sustained-release formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Optimization of plasmid vectors for high-level expression in lung epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

The body as a manufacturer of endostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

7 January 2021

Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

7 January 2021

Cancer therapy. Setbacks for endostatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

7 January 2021

Contribution of Plasmid DNA to Inflammation in the Lung after Administration of Cationic Lipid:pDNA Complexes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700704

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700704

1 reference

6 February 2018

1 reference

6 February 2018